Multicenter Single Arm Phase II Study of Single Agent Palifosfamide in Recurrent and Incurable Germ Cell Tumors
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2015
Price : $35 *
At a glance
- Drugs Palifosfamide (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 01 Feb 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.